Unknown

Dataset Information

0

Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.


ABSTRACT: Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 studies as an oral extended-release (ER) formulation administered once daily. The purpose of this study was to develop a level A in vitro-in vivo correlation (IVIVC) for upadacitinib ER formulation. The pharmacokinetics of four upadacitinib extended-release formulations with different in vitro release characteristics and an immediate-release capsule formulation of upadacitinib were evaluated in 20 healthy subjects in a single-dose, randomized, crossover study. In vivo pharmacokinetic data and in vitro dissolution data (USP Dissolution Apparatus 1; pH 6.8; 100 rpm) were used to establish a level A IVIVC. Three formulations were used to establish the IVIVC, and the fourth formulation was used for external validation. A non-linear IVIVC best described the relationship between upadacitinib in vitro dissolution and in vivo absorption profiles. The absolute percent prediction errors (%PE) for upadacitinib Cmax and AUC were less than 10% for all three formulations used to establish the IVIVC, as well as for the %PE for the external validation formulation and the overall mean internal validation. Model was cross-validated using the leave-one-out approach; all evaluated cross-validation runs met the regulatory acceptance criteria. A level A IVIVC was successfully developed and validated for upadacitinib ER formulation, which meets the FDA and EMA regulatory validation criteria and can be used as surrogate for in vivo bioequivalence.

SUBMITTER: Mohamed MF 

PROVIDER: S-EPMC6814631 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.

Mohamed Mohamed-Eslam F MF   Trueman Sheryl S   Othman Ahmed A AA   Othman Ahmed A AA   Han Jian-Hwa JH   Ju Tzuchi R TR   Marroum Patrick P  

The AAPS journal 20191025 6


Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis. Upadacitinib was evaluated in Phase 3 studies as an oral extended-release (ER) formulation administered once daily. The purpose of this study was to develop a level A in vitro-in vivo correlation (IVIVC) for upadacitinib ER formulation. The pharmacokinetics of four upadacitinib extended-release formulations with different in vitro releas  ...[more]

Similar Datasets

| S-EPMC10787209 | biostudies-literature
| S-EPMC7027977 | biostudies-literature
| S-EPMC6996546 | biostudies-literature
| S-EPMC9323828 | biostudies-literature
| S-EPMC6985042 | biostudies-literature
| S-EPMC3671720 | biostudies-literature
| S-EPMC2063566 | biostudies-other
| S-EPMC6620107 | biostudies-literature
| S-EPMC10192681 | biostudies-literature
| S-EPMC6044685 | biostudies-literature